PMID- 33866775
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20240213
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 45
IP  - 3
DP  - 2021 May
TI  - Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes 
      Mellitus.
PG  - 326-336
LID - 10.4093/dmj.2020.0272 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and beta-cell 
      dysfunction. Among available oral antidiabetic agents, only the 
      thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve 
      insulin sensitivity by activating peroxisome proliferator-activated receptor gamma. 
      Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to 
      their potent glycemic efficacy and low risk of hypoglycemia. However, their use 
      has decreased because of side effects and safety issues, such as cardiovascular 
      concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical 
      Corporation), a novel TZD, was developed to meet the demands for an effective and 
      safe TZD. Lobeglitazone shows similar glycemic efficacy to pioglitazone, with a 
      lower effective dose, and favorable safety results. It also showed pleiotropic 
      effects in preclinical and clinical studies. In this article, we summarize the 
      pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone.
FAU - Bae, Jaehyun
AU  - Bae J
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      International St. Mary's Hospital, Catholic Kwandong University College of 
      Medicine, Incheon, Korea.
FAU - Park, Taegyun
AU  - Park T
AD  - Department of Clinical Research Design and Evaluation, Samsung Advanced Institute 
      for Health Sciences & Technology, Sungkyunkwan University, Seoul, Korea.
FAU - Kim, Hyeyoung
AU  - Kim H
AD  - Medical information and Pharmacovigilance Team, CKD Pharmaceutical Corp., Seoul, 
      Korea.
FAU - Lee, Minyoung
AU  - Lee M
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Korea.
FAU - Cha, Bong-Soo
AU  - Cha BS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210419
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pyrimidines)
RN  - 0 (Thiazolidinediones)
RN  - MY89F08K5D (lobeglitazone)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Pyrimidines
MH  - *Thiazolidinediones/adverse effects
PMC - PMC8164939
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Lobeglitazone
OT  - Thiazolidinediones
COIS- CONFLICTS OF INTEREST The authors report no potential conflict of interest 
      relevant to this article. Laboratory data analysis and calibration support was 
      provided by Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea.
EDAT- 2021/04/20 06:00
MHDA- 2023/02/25 06:00
PMCR- 2021/05/01
CRDT- 2021/04/19 03:30
PHST- 2020/11/16 00:00 [received]
PHST- 2021/02/23 00:00 [accepted]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2021/04/19 03:30 [entrez]
PHST- 2021/05/01 00:00 [pmc-release]
AID - dmj.2020.0272 [pii]
AID - dmj-2020-0272 [pii]
AID - 10.4093/dmj.2020.0272 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2021 May;45(3):326-336. doi: 10.4093/dmj.2020.0272. Epub 2021 
      Apr 19.